(E)-3-(methoxycarbonyl)-4-(m-tolyl)but-3-enoic acid | 145324-53-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-3-(methoxycarbonyl)-4-(m-tolyl)but-3-enoic acid
• 英文别名: (E)-3-methoxycarbonyl-4-(3-methylphenyl)-3-butenoic acid；(E)-3-methoxycarbonyl-4-(3-methylphenyl)but-3-enoic acid
• CAS: 145324-53-4
• 化学式: C₁₃H₁₄O₄
• 分子量: 234.252
• InChiKey: FMXLYRFKMAQCIB-YRNVUSSQSA-N

物化性质

• 沸点：
  395.3±30.0 °C(Predicted)
• 密度：
  1.206±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (E)-3-(methoxycarbonyl)-4-(m-tolyl)but-3-enoic acid 、 顺式-2,3,3a,4,7,7a-六氢-1H-异吲哚 、 氯甲酸异丁酯 在 N-甲基吗啉 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 methyl (E)-2-(3-methylbenzylidene)-3-(cis-3a,4,7,7a-tetrahydro-2-isoindolinylcarbonyl)propionate
  参考文献：
  名称：

  Succinic acid compounds

  摘要：

  Succinic acid compounds of the formula: ##STR1## wherein A represents a heterocyclic group, a 3 to 8-membered cycloalkyl group or a phenyl group which may have one or more substituents selected from the group of a halogen atom, a lower alkyl group having 1 to 6 carbon atoms and a lower alkoxy group having 1 to 6 carbon atoms; B represents a bicyclic amino group which may have 1 or 2 unsaturated bonds, with the proviso that B bonds to the carbon atom of the carbonyl group at the nitrogen atom; R represents a hydrogen atom or combines each other to form a chemical bond; R.sup.1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 10 carbon atoms; when there is an asymmetric carbon atom, enantiomers thereof and racemic mixtures thereof; when there are geometrical isomers, each geometrical isomer, E-isomers thereof, Z-isomers thereof, cis-isomers thereof and trans-isomers thereof; and pharmaceutically acceptable salts thereof, enhance insulin secretion and possess a hypoglycemic activity, and are thus useful for the treatment of diabetes.

  公开号：

  US05202335A1
• 作为产物：
  描述：

  sodium methylate 、 3-甲基苯甲醛 、 丁二酸二甲酯 在 水 、 乙醚 、 Brine 、 magnesium sulfate 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以to give 3.8 g of的产率得到(E)-3-(methoxycarbonyl)-4-(m-tolyl)but-3-enoic acid
  参考文献：
  名称：

  Succinic acid compounds

  摘要：

  分子式为：##STR1##的琥珀酸化合物，其中A代表杂环基团、3至8个成员的环烷基团或苯基团，其可具有来自卤素原子、1至6个碳原子的低烷基团和1至6个碳原子的低烷氧基团等基团的一个或多个取代基；B代表一个含有1或2个不饱和键的双环氨基团，但B必须与氮原子的羰基团上的碳原子成键；R代表氢原子或结合在一起形成化学键；R.sup.1代表氢原子、1至6个碳原子的低烷基团或7至10个碳原子的芳基烷基团；当存在不对称碳原子时，其对映异构体和外消旋混合物；当存在几何异构体时，每个几何异构体、E-异构体、Z-异构体、顺式异构体和反式异构体；以及其药学上可接受的盐，可以增强胰岛素分泌并具有降血糖作用，因此可用于治疗糖尿病。

  公开号：

  US05202335A1

文献信息

• SELECTIVE INHIBITORS FOR TRANSFERASES
  申请人：Reinberg Danny

  公开号：US20090306201A1

  公开（公告）日：2009-12-10

  A pharmaceutical composition comprising a compound of formula I or II and a pharmaceutically acceptable carrier. Methods for treating a proliferative disorder mediated by a methyl transferase comprising administering an anti-proliferative effective amount of the compound of formula I or II are also presented.

  一种药物组合物，包括公式I或II的化合物和药用载体。还提供了通过给予公式I或II化合物的抗增殖有效量来治疗由甲基转移酶介导的增殖性疾病的方法。
• A highly regio- and stereoselective Pd-catalyzed electrocarboxylation of Baylis-Hillman acetates: An interesting switchable regioselectivity based on electrode material
  作者：Satyanarayana Tummanapalli、Kali Charan Gulipalli、Srinivas Endoori、Srinu Bodige、Anil Kumar Pommidi、Srinivas Medaboina、Swathi Rejinthala、Suresh Choppadandi、Ravi Boya、Ashok Kanuka、Muralikrishna Valluri

  DOI：10.1016/j.tetlet.2022.154022

  日期：2022.8

  regio- and stereoselective palladium catalyzed electrocarboxylation of Baylis-Hillman acetates. We found an interesting unprecedented electrode material-controlled switchable regioselectivity. When Platinum was taken as cathode, benzylic carboxylation products were found to be the predominant regioisomers (condition A). Under similar reaction conditions when Nickel was taken as cathode, a complete reversal

  我们开发了一种新型的区域选择性和立体选择性钯催化 Baylis-Hillman 醋酸盐的电羧化反应。我们发现了一种有趣的、前所未有的电极材料控制的可切换区域选择性。当铂作为阴极时，发现苄基羧化产物是主要的区域异构体（条件 A）。在以镍为阴极的类似反应条件下，观察到区域选择性完全逆转，提供肉桂基羧化产物作为主要的区域异构体，仅具有 (E)-立体化学（条件 B）。我们提出了合理的机制来解释区域选择性的转换，这得到了 TEMPO 实验的进一步支持。
• US5202335A
  申请人：——

  公开号：US5202335A

  公开（公告）日：1993-04-13
• Succinic acid compounds
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US05202335A1

  公开（公告）日：1993-04-13

  Succinic acid compounds of the formula: ##STR1## wherein A represents a heterocyclic group, a 3 to 8-membered cycloalkyl group or a phenyl group which may have one or more substituents selected from the group of a halogen atom, a lower alkyl group having 1 to 6 carbon atoms and a lower alkoxy group having 1 to 6 carbon atoms; B represents a bicyclic amino group which may have 1 or 2 unsaturated bonds, with the proviso that B bonds to the carbon atom of the carbonyl group at the nitrogen atom; R represents a hydrogen atom or combines each other to form a chemical bond; R.sup.1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 10 carbon atoms; when there is an asymmetric carbon atom, enantiomers thereof and racemic mixtures thereof; when there are geometrical isomers, each geometrical isomer, E-isomers thereof, Z-isomers thereof, cis-isomers thereof and trans-isomers thereof; and pharmaceutically acceptable salts thereof, enhance insulin secretion and possess a hypoglycemic activity, and are thus useful for the treatment of diabetes.

  Succinic acid compounds of the formula: ##STR1## wherein A represents a heterocyclic group, a 3 to 8-membered cycloalkyl group or a phenyl group which may have one or more substituents selected from the group of a halogen atom, a lower alkyl group having 1 to 6 carbon atoms and a lower alkoxy group having 1 to 6 carbon atoms; B represents a bicyclic amino group which may have 1 or 2 unsaturated bonds, with the proviso that B bonds to the carbon atom of the carbonyl group at the nitrogen atom; R represents a hydrogen atom or combines each other to form a chemical bond; R.sup.1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 10 carbon atoms; when there is an asymmetric carbon atom, enantiomers thereof and racemic mixtures thereof; when there are geometrical isomers, each geometrical isomer, E-isomers thereof, Z-isomers thereof, cis-isomers thereof and trans-isomers thereof; and pharmaceutically acceptable salts thereof, enhance insulin secretion and possess a hypoglycemic activity, and are thus useful for the treatment of diabetes.